To assess the potential for cross-protection among genital human papillomavirus (HPV)
types in virus-like particle (VLP)-based vaccinations, inhibition of HPV VLP-mediated …

Recombinant human papillomavirus (HPV) virus-like particles (VLPs) are promising vaccine
candidates for controlling anogenital HPV disease. Questions remain, however, concerning …

ABSTRACT Human papillomavirus type 16 (HPV-16) is strongly associated with the
development of cervical cancer. Studies of model systems with animal papillomaviruses …

The available virus-like particle (VLP)-based prophylactic vaccines against specific human
papillomavirus (HPV) types afford close to 100% protection against the type-associated …

The variable surface loops on human papillomavirus (HPV) virions required for type-specific
neutralization by human sera remain poorly defined. To determine which loops are required …

Recombinant human papillomavirus type 11 (HPV-11) virus-like particles (VLPs) were
tested for their ability to induce the formation of neutralizing antibodies, and were also tested …

Vaccination with papillomavirus L2 has been shown to induce neutralizing antibodies that
protect against homologous type infection and cross-neutralize a limited number of genital …

Vaccination with virus-like particles (VLP), comprising both L1 and L2 of human
papillomavirus (HPV) genital types 6, 16, and 18, induces predominantly type-specific …

Antibodies reactive to HPV types 6 and 11 were tested in ELISA and HPV-11 neutralization
assays to determine whether these closely related types shared cross-reactive neutralizing …

It has been shown previously that immunization of animals with recombinant virus-like
particles (VLPs) consisting of the viral capsid proteins L1 or L1 plus L2 protected animals …